ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
7.88
+0.09 (1.16%)
At close: Jul 14, 2026, 4:00 PM EDT
7.95
+0.07 (0.90%)
After-hours: Jul 14, 2026, 7:59 PM EDT
ImmunityBio Market Cap
ImmunityBio has a market cap or net worth of $8.25 billion as of July 14, 2026. Its market cap has increased by 246.32% in one year.
Market Cap
8.25B
Enterprise Value
9.00B
1-Year Change
246.32%
Ranking
Category
Stock Price
$7.88
Market Cap Chart
Since March 10, 2021, ImmunityBio's market cap has decreased from $14.82B to $8.25B, a decrease of -44.32%. That is a compound annual growth rate of -10.37%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 14, 2026 | 8.25B | 323.19% |
| Dec 31, 2025 | 1.95B | 4.33% |
| Dec 31, 2024 | 1.87B | -44.23% |
| Dec 29, 2023 | 3.35B | 61.49% |
| Dec 30, 2022 | 2.08B | -14.18% |
| Dec 31, 2021 | 2.42B | -83.68% |
| Mar 10, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Kymera Therapeutics | 9.22B |
| Praxis Precision Medicines | 9.14B |
| Ionis Pharmaceuticals | 9.08B |
| Halozyme Therapeutics | 8.90B |
| Crinetics Pharmaceuticals | 8.83B |
| Spyre Therapeutics | 8.70B |
| Protagonist Therapeutics | 8.44B |
| Vaxcyte | 8.12B |